Literature DB >> 29792893

TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection.

Ting Chen1, Qing Li1, Xiaoyan Zhang2, Ran Long3, Yaxin Wu1, Jiao Wu1, Xiangsheng Fu4.   

Abstract

Fusobacterium nucleatum in the tumor microenvironment plays an important role in the development of colorectal cancer. The underlying mechanism of action, however, remains to be elucidated. We evaluated the relation of F nucleatum amount to thymocyte selection-associated high-mobility group box (TOX) protein expression and CD4+ T-cell density in 138 human colorectal tissues. TOX expression and CD4+ T-cell density in Fnucleatum-negative tissues were significantly higher compared to those in Fnucleatum-positive tissues (P < .001 and P = .002, respectively). We found a negative correlation between F nucleatum abundance and TOX expression (P < .001) and CD4+ T-cell density (P < .001). TOX expression in normal mucosa, hyperplastic polyps, and adenomas was significantly higher than in sessile serrated adenomas and different stages of carcinomas (P < .05). Moreover, CD4+ T-cell density in high-TOX expression tissues was significantly higher than in low-TOX expression tissues (P = .003). A positive correlation was found between TOX expression and CD4+ T-cell density in colorectal tissues (Spearman correlation coefficient: 0.362, 95% confidence interval: 0.051-0.641, P = .022). Our findings suggest that F nucleatum may suppress antitumor immune responses by decreasing CD4+ T-cell density and TOX expression in the progression of colorectal cancer.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Antitumor; Colorectal cancer; Fusobacterium nucleatum; T cells; TOX

Mesh:

Substances:

Year:  2018        PMID: 29792893     DOI: 10.1016/j.humpath.2018.05.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Autoinducer-2 of gut microbiota, a potential novel marker for human colorectal cancer, is associated with the activation of TNFSF9 signaling in macrophages.

Authors:  Qing Li; Wei Peng; Jiao Wu; Xianfei Wang; Yixing Ren; Huan Li; Yan Peng; Xiaowei Tang; Xiangsheng Fu
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

Review 2.  The interaction between gut microbiome and anti-tumor drug therapy.

Authors:  Chen Fu; Ziting Yang; Jiankun Yu; Minjie Wei
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

3.  Expression pattern, regulation, and clinical significance of TOX in breast cancer.

Authors:  Mohit Arora; Sarita Kumari; Jay Singh; Anita Chopra; Shyam S Chauhan
Journal:  Cancer Immunol Immunother       Date:  2020-08-05       Impact factor: 6.968

4.  Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.

Authors:  Lishay Parhi; Tamar Alon-Maimon; Asaf Sol; Deborah Nejman; Amjad Shhadeh; Tanya Fainsod-Levi; Olga Yajuk; Batya Isaacson; Jawad Abed; Naseem Maalouf; Aviram Nissan; Judith Sandbank; Einav Yehuda-Shnaidman; Falk Ponath; Jörg Vogel; Ofer Mandelboim; Zvi Granot; Ravid Straussman; Gilad Bachrach
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 14.919

Review 5.  Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa.

Authors:  Garreth W Lawrence; Máire Begley; Paul D Cotter; Caitriona M Guinane
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

6.  Comparison of clinicopathological parameters, prognosis, micro-ecological environment and metabolic function of Gastric Cancer with or without Fusobacterium sp. Infection.

Authors:  Siru Nie; Ang Wang; Yuan Yuan
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

7.  Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System.

Authors:  Jawad Abed; Naseem Maalouf; Abigail L Manson; Ashlee M Earl; Lishay Parhi; Johanna E M Emgård; Michael Klutstein; Shay Tayeb; Gideon Almogy; Karine A Atlan; Stella Chaushu; Eran Israeli; Ofer Mandelboim; Wendy S Garrett; Gilad Bachrach
Journal:  Front Cell Infect Microbiol       Date:  2020-08-07       Impact factor: 5.293

Review 8.  The Four Horsemen in Colon Cancer.

Authors:  Marco Antonio Hernández-Luna; Sergio López-Briones; Rosendo Luria-Pérez
Journal:  J Oncol       Date:  2019-09-29       Impact factor: 4.375

9.  LncRNA MALAT1 Suppression Protects Endothelium against oxLDL-Induced Inflammation via Inhibiting Expression of MiR-181b Target Gene TOX.

Authors:  Liuqing Wang; Yinliang Qi; Yi Wang; Haitao Tang; Zhenzhen Li; Yuan Wang; Songtao Tang; Huaqing Zhu
Journal:  Oxid Med Cell Longev       Date:  2019-12-14       Impact factor: 6.543

10.  FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2.

Authors:  Pin Guo; Zibin Tian; Xinjuan Kong; Lin Yang; Xinzhi Shan; Bingzi Dong; Xueli Ding; Xue Jing; Chen Jiang; Na Jiang; Yanan Yu
Journal:  J Exp Clin Cancer Res       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.